Further experience with OK-432 for lymphangiomas

Area of Science:

• Pediatric Surgery
• Oncology
• Immunotherapy

Background:

• Lymphangioma is a benign congenital tumor that can cause significant morbidity in children.
• Traditional treatments like surgery can be invasive and may lead to complications.
• OK-432 (a streptococcal preparation) has emerged as a potential immunotherapeutic agent for lymphangioma.

Purpose of the Study:

• To evaluate the efficacy and long-term outcomes of OK-432 therapy in pediatric lymphangioma patients.
• To analyze factors influencing treatment response, such as cyst size.
• To assess the safety profile and recurrence rates associated with OK-432 treatment.

Main Methods:

• Retrospective analysis of 29 pediatric patients treated with OK-432 for lymphangioma between 1999-2003.
• Review of 15 previously treated patients for long-term follow-up data.
• Assessment of treatment outcomes based on cyst regression, adverse reactions, and recurrence.

Main Results:

• Complete regression occurred in 12 patients, and >50% regression in 8 patients; 7 showed no change.
• Larger cyst size correlated with a better treatment prognosis.
• Long-term follow-up revealed recurrence in 4 of 15 previously treated patients, with 11 remaining disease-free.

Conclusions:

• OK-432 therapy is an effective first-line treatment for pediatric lymphangioma, achieving significant regression and avoiding surgery in most cases.
• The risk of recurrence exists but does not negate the overall benefit of OK-432 therapy.
• OK-432 offers a favorable risk-benefit profile for managing pediatric lymphangioma.